Search

Displaying results 8521 - 8530 of 10000 in total
  1. Drug

    Plumbagin

    go.drugbank.com/drugs/DB17048
    Investigational

    Plumbagin is a compound investigated for its anticancer activity. It has been found that it inactivates the Akt/NF-kB, MMP-9 and VEGF pathways.[A253102]

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    RS-39604

    go.drugbank.com/drugs/DB17050
    Experimental

    RS-39604 is a selective 5-HT4 receptor antagonist.[A253112]

  3. Drug

    SB-218078

    go.drugbank.com/drugs/DB17051
    Experimental

    SB-218078 is a specific inhibitor of CHK1.[A253117]

  4. Drug

    Scriptaid

    go.drugbank.com/drugs/DB17053
    Experimental

    Scriptaid is a histone deacetylase (HDAC) inhibitor researched for its anti-tumor properties.[A253127]

    Synonyms: 1h-benz(de)isoquinoline-2(3h)-hexanamide, n-hydroxy-1,3-dioxo-, N-hydroxy-1,3-dioxo-1h-benz(de)isoquinoline-2(3h)-hexan amide
  5. Drug

    SKF-96365 free base

    go.drugbank.com/drugs/DB17054
    Experimental

    SKF-96365 is a receptor-mediated calcium entry (RMCE) inhibitor structurally different from other calcium antagonists.[A253132]

  6. Drug

    SNX-2112

    go.drugbank.com/drugs/DB17055
    Experimental

    SNX-2112 is a heat shock protein 90 (Hsp90) inhibitor.[A253137]

  7. Drug

    JZP-386 free base

    go.drugbank.com/drugs/DB17068
    Experimental

    JZP-386 is a deuterium-containing analog of sodium oxybate. Its safety, pharmacokinetics and pharmacodynamics were evaluated in clinical trial NCT02215499.

  8. Drug

    MYR-101

    go.drugbank.com/drugs/DB17075
    Investigational

    It is caused by a mutation in the aspartoacylase gene (_ASPA_), which leads to a deficiency of the aspartoacylase enzyme (ASPA). … Canavan disease is a fatal childhood genetic disorder characterized by white matter degeneration in the brain.

  9. Drug

    Sipagladenant

    go.drugbank.com/drugs/DB17080
    Investigational

    KW-6356 is a selective antagonist of adenosine A2A receptors developed by Kyowa Kirin.[L43822]

  10. Drug

    Tinlorafenib

    go.drugbank.com/drugs/DB17082
    Investigational

    Tinlorafenib (PF-07284890) is a potent, selective, highly brain-penetrant, small-molecule inhibitor of BRAF V600 mutations.[A253992]